Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2004 April;70(4) > Minerva Anestesiologica 2004 April;70(4):245-50

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

CARDIOVASCULAR  SMART 2004 - Milan, May 12-14, 2004 Freefree

Minerva Anestesiologica 2004 April;70(4):245-50

Copyright © 2004 EDIZIONI MINERVA MEDICA

language: Italian

Administration of inhaled nitric oxide in newborns

Biban P.

Terapia Intensiva Neonatale e Pediatrica, Divisione di Pediatria, Ospedale Civile Maggiore, Azienda Ospedaliera di Verona, Verona


PDF


The use of inhaled nitric oxide (iNO) in newborn hypoxemic respiratory failure is based on the evidence of selective pulmonary vasodilation, without systemic side effects.
It is usedin more than 34 weeks old newborns, with severe acute pulmonary hypertension and right-left extrapulmonary shunt. In the other cases (i.e. pneumonia, sepsis, ARDS), the therapeutic effect is less evident; no final data are available on the use of iNO in pre-term babies.
The recommended dosage is 20 ppm, scaling down until 5 ppm and the 40 ppm should never be reached. The length of treatment is variable, usually no more than 7 days and the weaning should be progressive.
In conclusion,the use of iNO in newborns with persistent pulmonary hypertension reduces the need of ECMO, but does not substantially modify the outcome.

top of page